Cargando…
A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats
BACKGROUND: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240275/ https://www.ncbi.nlm.nih.gov/pubmed/30447687 http://dx.doi.org/10.1186/s12933-018-0790-0 |
_version_ | 1783371611769929728 |
---|---|
author | Durak, Aysegul Olgar, Yusuf Degirmenci, Sinan Akkus, Erman Tuncay, Erkan Turan, Belma |
author_facet | Durak, Aysegul Olgar, Yusuf Degirmenci, Sinan Akkus, Erman Tuncay, Erkan Turan, Belma |
author_sort | Durak, Aysegul |
collection | PubMed |
description | BACKGROUND: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor dapagliflozin (DAPA)-related cardioprotection in overweight insulin-resistant MetS-rats comparison with insulin (INSU), behind its glucose-lowering effect. METHODS: A 28-week high-carbohydrate diet-induced MetS-rats received DAPA (5 mg/kg), INSU (0.15 mg/kg) or vehicle for 2 weeks. To validate MetS-induction, we monitored all animals weekly by measuring body weight, blood glucose and HOMO-IR index, electrocardiograms, heart rate, systolic and diastolic pressures. RESULTS: DAPA-treatment of MetS-rats significantly augmented the increased blood pressure, prolonged Q–R interval, and low heart rate with depressed left ventricular function and relaxation of the aorta. Prolonged-action potentials were preserved with DAPA-treatment, more prominently than INSU-treatment, at most, through the augmentation in depressed voltage-gated K(+)-channel currents. DAPA, more prominently than INSU-treatment, preserved the depolarized mitochondrial membrane potential, and altered mitochondrial protein levels such as Mfn-1, Mfn-2, and Fis-1 as well as provided significant augmentation in cytosolic Ca(2+)-homeostasis. Furthermore, DAPA also induced significant augmentation in voltage-gated Na(+)-currents and intracellular pH, and the cellular levels of increased oxidative stress, protein-thiol oxidation and ADP/ATP ratio in cardiomyocytes from MetS rats. Moreover, DAPA-treatment normalized the increases in the mRNA level of SGLT2 in MetS-rat heart. CONCLUSIONS: Overall, our data provided a new insight into DAPA-associated cardioprotection in MetS rats, including suppression of prolonged ventricular-repolarization through augmentation of mitochondrial function and oxidative stress followed by improvement of fusion–fission proteins, out of its glucose-lowering effect. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12933-018-0790-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6240275 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-62402752018-11-23 A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats Durak, Aysegul Olgar, Yusuf Degirmenci, Sinan Akkus, Erman Tuncay, Erkan Turan, Belma Cardiovasc Diabetol Original Investigation BACKGROUND: Metabolic syndrome (MetS) is a prevalent risk factor for cardiac dysfunction. Although SGLT2-inhibitors have important cardioprotective effects in hyperglycemia, their underlying mechanisms are complex and not completely understood. Therefore, we examined mechanisms of a SGLT2-inhibitor dapagliflozin (DAPA)-related cardioprotection in overweight insulin-resistant MetS-rats comparison with insulin (INSU), behind its glucose-lowering effect. METHODS: A 28-week high-carbohydrate diet-induced MetS-rats received DAPA (5 mg/kg), INSU (0.15 mg/kg) or vehicle for 2 weeks. To validate MetS-induction, we monitored all animals weekly by measuring body weight, blood glucose and HOMO-IR index, electrocardiograms, heart rate, systolic and diastolic pressures. RESULTS: DAPA-treatment of MetS-rats significantly augmented the increased blood pressure, prolonged Q–R interval, and low heart rate with depressed left ventricular function and relaxation of the aorta. Prolonged-action potentials were preserved with DAPA-treatment, more prominently than INSU-treatment, at most, through the augmentation in depressed voltage-gated K(+)-channel currents. DAPA, more prominently than INSU-treatment, preserved the depolarized mitochondrial membrane potential, and altered mitochondrial protein levels such as Mfn-1, Mfn-2, and Fis-1 as well as provided significant augmentation in cytosolic Ca(2+)-homeostasis. Furthermore, DAPA also induced significant augmentation in voltage-gated Na(+)-currents and intracellular pH, and the cellular levels of increased oxidative stress, protein-thiol oxidation and ADP/ATP ratio in cardiomyocytes from MetS rats. Moreover, DAPA-treatment normalized the increases in the mRNA level of SGLT2 in MetS-rat heart. CONCLUSIONS: Overall, our data provided a new insight into DAPA-associated cardioprotection in MetS rats, including suppression of prolonged ventricular-repolarization through augmentation of mitochondrial function and oxidative stress followed by improvement of fusion–fission proteins, out of its glucose-lowering effect. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12933-018-0790-0) contains supplementary material, which is available to authorized users. BioMed Central 2018-11-17 /pmc/articles/PMC6240275/ /pubmed/30447687 http://dx.doi.org/10.1186/s12933-018-0790-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Investigation Durak, Aysegul Olgar, Yusuf Degirmenci, Sinan Akkus, Erman Tuncay, Erkan Turan, Belma A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats |
title | A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats |
title_full | A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats |
title_fullStr | A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats |
title_full_unstemmed | A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats |
title_short | A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats |
title_sort | sglt2 inhibitor dapagliflozin suppresses prolonged ventricular-repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240275/ https://www.ncbi.nlm.nih.gov/pubmed/30447687 http://dx.doi.org/10.1186/s12933-018-0790-0 |
work_keys_str_mv | AT durakaysegul asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT olgaryusuf asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT degirmencisinan asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT akkuserman asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT tuncayerkan asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT turanbelma asglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT durakaysegul sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT olgaryusuf sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT degirmencisinan sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT akkuserman sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT tuncayerkan sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats AT turanbelma sglt2inhibitordapagliflozinsuppressesprolongedventricularrepolarizationthroughaugmentationofmitochondrialfunctionininsulinresistantmetabolicsyndromerats |